Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 202
STOCKHOLM, July 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
Source: europapress.es